Bessemer Group
BPMC

Bessemer Group’s Blueprint Medicines BPMC Stock Holding History

Bessemer Group’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-174
Closed -$22K – 2495
2025
Q2 		$22K Buy
174
+14
+9% +$1.45K ﹤0.01% 1543
2025
Q1 		$14K Sell
160
-77
-32% -$7.51K ﹤0.01% 1637
2024
Q4 		$21K Sell
237
-765
-76% -$70.1K ﹤0.01% 1500
2024
Q3 		$92K Buy
1,002
+157
+19% +$15.6K ﹤0.01% 1296
2024
Q2 		$91K Hold
845
– – ﹤0.01% 1191
2024
Q1 		$80K Hold
845
– – ﹤0.01% 1213
2023
Q4 		$78K Buy
845
+51
+6% +$3.3K ﹤0.01% 1262
2023
Q3 		$40K Hold
794
– – ﹤0.01% 1372
2023
Q2 		$50K Hold
794
– – ﹤0.01% 1376
2023
Q1 		$36K Buy
+794
New +$35.8K ﹤0.01% 1279
2020
Q3 		– Sell
-5,100
Closed -$398K – 1373
2020
Q2 		$398K Buy
+5,100
New +$345K ﹤0.01% 1021

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Bessemer Group's BPMC Position: Q3 2025 in Review

Bessemer Group sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 174 shares — an estimated $22K sold.

Bessemer Group first reported a position in BPMC in Q2 2020 and held it in 11 quarters. The position peaked at $398K in Q2 2020. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Bessemer Group reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Bessemer Group sold 174 Blueprint Medicines shares in Q3 2025, an estimated $22K.
  • Bessemer Group first reported a position in Blueprint Medicines in Q2 2020 and held it in 11 quarters.
  • Bessemer Group's Blueprint Medicines position peaked at $398K in Q2 2020.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Bessemer Group's 13F filing for Q3 2025, filed 5 Nov 2025.